Biogen's Aducanumab Fails To Win FDA Panel Backing
November 07, 2020 at 15:36 PM EST
Biogen Inc. failed to win the backing of the FDA panel which reviewed the BLA for its controversial Alzheimer's drug aducanumab, an antibody which targets amyloid-beta.